CATB

Catabasis Pharmaceuticals, Inc. (CATB) | Rumor.io

Catabasis Pharmaceuticals

CATB

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about CATB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Apr 29

Catabasis Pharmaceuticals' asset, $CATB, is launching a new project in decentralized finance.
The project, led by a large development team, features a 0/0 tax model and a minting mechanism.
Market participants are optimistic about $CATB's prospects, citing its solid team and potential for growth.

Generated by AI

Sentiment

Of the messages about CATB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +40
Bearish	—	—	—	0% -40

Bullish· Jan 29

$CATB has already reached $7, up 200% from its previous price, with strong volume of over 100 million shares traded.
The asset has shown significant price increases, doubling from $2.50 to $5 on strong volume, and has the potential for further growth with algo volume and high trading activity.
$CATB has seen impressive price gains, with some investors experiencing up to 4000% returns in less than an hour, and is considered a strong candidate for future growth with its recent deal to buy Quellis Biosciences.

Bearish· Oct 27

$CATB is experiencing a dead cat bounce and trading below cash, making it a high-risk investment.
The company's failed clinical trial has led to a significant decline in its stock price, with a 64% drop after phase 3 fail news.
The stock's recent price drop to 1.93 is a significant loss, and investors are advised to be cautious and potentially reevaluate their investment in $CATB.

Generated by AI

Topics

Of the messages about CATB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	50%	50%	50%	49.08%
Announcements	0%	0%	0%	1.1%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0.74%
Macro	50%	50%	50%	49.08%
Technical Analysis	0%	0%	0%	0%

Earnings· Aug 9

Catabasis Pharmaceuticals, Inc. ($CATB) is hosting its Q2 earnings call today at 8:30am Eastern, which can be streamed live or accessed on replay.

Analysts· Oct 5

Catabasis Pharmaceuticals ($CATB) has received a price target increase to $7 from $4 at Oppenheimer.
Oppenheimer has reiterated an Outperform rating on $CATB and raised its price target to $7.
Citigroup has raised its price target on $CATB to $3.50.

Announcements· Aug 20

Catabasis Pharmaceuticals, Inc. (CATB) has no announcements in the provided social media posts.
No announcements related to Catabasis Pharmaceuticals, Inc. (CATB) were found.
There are no relevant announcements about Catabasis Pharmaceuticals, Inc. (CATB) in the provided social media posts.

Generated by AI

Community

Of the messages about CATB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	1.82%
Newcomers	100%	100%	100%	98.18%

Regulars· Aug 20

Catella released a strong report for the second quarter, with all aspects being positive according to the analyst.
Catabasis Pharmaceuticals, Inc. filed a Form 8-K regarding a material modification to its rights of security holders and amendments to its articles of incorporation.
The company's stock was up 4.6% after a 15:39 pop, with a notable loss of $970 on a buy of 1000 shares.

Newcomers· Aug 20

The newcomers are primarily discussing DarkPulse, Inc.'s subsidiary OPTILAN, which has won a security and comms contract for power plants constructed by ENKA INSAAT VE SANAYI A.S.
The focus is on the recent increase in stock ownership by PHI Group's chairman, which may have implications for the company's future.
The newcomers are also discussing Vitality Biopharma's entry into a $5 million equity line financing relationship with an institutional investor, which may have potential implications for the company's future.

Generated by AI

Also Discussed

Investors talking about CATB also mention

#	Name	Attention
1	XMax Inc.NVFY	0%0
2	Moleculin Biotech, Inc.MBRX	0%0
3	Solid Biosciences Inc.SLDB	0.3%new
4	Capricor Therapeutics, Inc.CAPR	0.35%+0.26
5	HTGM - HTG Molecular Diagnostics, Inc.	——
6	CBLI - Cytocom, Inc.	——
7	BCEI - Civitas Resources, Inc.	——
8	Crescent Biopharma Inc.CBIO	0%new
9	ONCS - OncoSec Medical Incorporated	——
10	Pulmatrix Inc.PULM	0%0